Parkinson's Foundation Report issue

Foundation Phase 4

Organization Overview

First Clinical Trial
2019
NCT03924414
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Parkinson's Foundation

Active Ingredients

Drugs in Phase 4 Trials (1)

zoledronic acid (zometa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoporosis (Phase 4)

Parkinson Disease (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1